ArticleOncotarget2015
MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma.
Chao-Hua Chiu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this papertrialcites it